Compugen (NASDAQ:CGEN) Stock Rating Upgraded by HC Wainwright

Key Points

• HC Wainwright upgraded Compugen (NASDAQ:CGEN) to a "strong‑buy", while analyst opinions remain mixed — MarketBeat shows a consensus of "Moderate Buy" with an average price target of $4.00.
• CGEN shares opened at $1.72, trade near their 50‑ and 200‑day moving averages of $1.58, have a market cap of $138.3M, a negative P/E (-5.73) and a beta of 2.85, with a one‑year range of $1.13–$2.66.
• The company beat Q results (EPS -$0.07 vs. -$0.09 estimate; revenue $1.89M vs. $1.47M) but remains unprofitable with a negative net margin and ROE, and institutional ownership is about 12.2% with notable increases by ARK and Jane Street.

Compugen (NASDAQ:CGEN - Get Free Report) was upgraded by HC Wainwright to a "strong-buy" rating in a report issued on Wednesday,Zacks.com reports.

CGEN has been the subject of several other reports. Wall Street Zen raised shares of Compugen from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compugen in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Compugen presently has a consensus rating of "Moderate Buy" and an average price target of $4.00.

Compugen Price Performance

Shares of CGEN stock opened at $1.72 on Wednesday. The firm's 50-day simple moving average is $1.58 and its 200-day simple moving average is $1.58. Compugen has a 1-year low of $1.13 and a 1-year high of $2.66. The firm has a market cap of $138.32 million, a P/E ratio of -5.73 and a beta of 2.85.

Compugen (NASDAQ:CGEN - Get Free Report) last released its earnings results on Monday, November 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. Compugen had a negative net margin of 400.10% and a negative return on equity of 53.60%. The firm had revenue of $1.89 million during the quarter, compared to the consensus estimate of $1.47 million. Analysts expect that Compugen will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Compugen

A number of institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its position in Compugen by 20.6% in the second quarter. ARK Investment Management LLC now owns 1,072,776 shares of the biotechnology company's stock valued at $1,785,000 after purchasing an additional 183,107 shares during the period. R Squared Ltd acquired a new stake in shares of Compugen in the second quarter valued at about $71,000. Franklin Resources Inc. purchased a new stake in shares of Compugen during the 2nd quarter valued at about $56,000. Jane Street Group LLC lifted its position in Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after acquiring an additional 359,785 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its position in Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company's stock worth $78,000 after acquiring an additional 34,045 shares in the last quarter. 12.22% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.